The association between fibrotic diseases and treatment resistant hypertension in England.

IF 7.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS European journal of preventive cardiology Pub Date : 2025-02-13 DOI:10.1093/eurjpc/zwaf068
G M Massen, P W Stone, R G Jenkins, R J Allen, L V Wain, I Stewart, U Tayal, J K Quint
{"title":"The association between fibrotic diseases and treatment resistant hypertension in England.","authors":"G M Massen, P W Stone, R G Jenkins, R J Allen, L V Wain, I Stewart, U Tayal, J K Quint","doi":"10.1093/eurjpc/zwaf068","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multimorbidity has been identified as a research priority in recent years, fibrosis (progressive organ scarring) is one mechanism which may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications), however it is not currently known whether severe hypertension is associated with fibrotic conditions.</p><p><strong>Objective: </strong>To investigate whether treatment resistant hypertension is associated with fibrotic conditions.</p><p><strong>Methods: </strong>We used the Clinical Practice Research Datalink (CPRD) Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (p<0.001) between hypertension control and each fibrotic condition respectively.</p><p><strong>Results: </strong>Of 1,340,495 people with hypertension during 2015, 83.50% (n=1,119,333) had managed hypertension either by lifestyle or medication; 16.50% (n=221,162) had treatment resistant hypertension. Fibrotic conditions were more common ((75.40% (95%CI: 75.20-75.60) vs. 68.90% (95%CI: 68.81-70.01)) in people with treatment resistant hypertension compared with those with managed hypertension. We found that treatment resistant hypertension was associated with; cardiomyopathy (ORadj:1.85, 95%CI:1.81-1.90), both type 1 and type 2 diabetes (ORadj:1.49,95%CI:1.44-1.55, ORadj:1.61,95%CI:1.60-1.63, respectively), liver fibrosis (ORadj:1.52, 95%CI: 1.46-1.58), valve fibrosis (ORadj:1.41, 95%CI:1.37-1.44) and urinary fibrosis (ORadj:1.41,95%CI:1.36-1.47).</p><p><strong>Conclusion: </strong>The proportion of people with fibrotic conditions was greater in those with treatment resistant hypertension than managed hypertension. The identified associations between treatment resistant hypertension and fibrotic conditions may point to common disease pathways which should be further explored to understand shared mechanisms.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwaf068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multimorbidity has been identified as a research priority in recent years, fibrosis (progressive organ scarring) is one mechanism which may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications), however it is not currently known whether severe hypertension is associated with fibrotic conditions.

Objective: To investigate whether treatment resistant hypertension is associated with fibrotic conditions.

Methods: We used the Clinical Practice Research Datalink (CPRD) Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (p<0.001) between hypertension control and each fibrotic condition respectively.

Results: Of 1,340,495 people with hypertension during 2015, 83.50% (n=1,119,333) had managed hypertension either by lifestyle or medication; 16.50% (n=221,162) had treatment resistant hypertension. Fibrotic conditions were more common ((75.40% (95%CI: 75.20-75.60) vs. 68.90% (95%CI: 68.81-70.01)) in people with treatment resistant hypertension compared with those with managed hypertension. We found that treatment resistant hypertension was associated with; cardiomyopathy (ORadj:1.85, 95%CI:1.81-1.90), both type 1 and type 2 diabetes (ORadj:1.49,95%CI:1.44-1.55, ORadj:1.61,95%CI:1.60-1.63, respectively), liver fibrosis (ORadj:1.52, 95%CI: 1.46-1.58), valve fibrosis (ORadj:1.41, 95%CI:1.37-1.44) and urinary fibrosis (ORadj:1.41,95%CI:1.36-1.47).

Conclusion: The proportion of people with fibrotic conditions was greater in those with treatment resistant hypertension than managed hypertension. The identified associations between treatment resistant hypertension and fibrotic conditions may point to common disease pathways which should be further explored to understand shared mechanisms.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
英国纤维化疾病与治疗难治性高血压之间的关系
背景:近年来,多发病已被确定为研究重点,纤维化(进行性器官瘢痕形成)可能是多发病的一种机制。一些研究表明高血压可能是纤维化的,特别是严重的高血压(药物无法控制),但目前尚不清楚严重高血压是否与纤维化有关。目的:探讨顽固性高血压是否与纤维化有关。方法:我们使用临床实践研究数据链(CPRD) Aurum初级保健数据库来定义2015年高血压患者队列。我们确定了有纤维化表现的人群的百分比,并探讨了高血压控制的差异。我们应用多变量logistic回归分析相关性(结果:2015年1340495例高血压患者中,83.50% (n= 1119333)通过生活方式或药物控制了高血压;16.50% (n=221,162)患有难治性高血压。与控制高血压患者相比,顽固性高血压患者的纤维化状况更为常见(75.40% (95%CI: 75.20-75.60) vs. 68.90% (95%CI: 68.81-70.01)。我们发现难治性高血压与;心肌病(ORadj:1.85, 95%CI:1.81-1.90), 1型和2型糖尿病(ORadj:1.49,95%CI:1.44-1.55, ORadj:1.61,95%CI:1.60-1.63),肝纤维化(ORadj:1.52, 95%CI: 1.46-1.58),瓣膜纤维化(ORadj:1.41,95%CI: 1.37-1.44)和尿纤维化(ORadj:1.41,95%CI:1.36-1.47)。结论:顽固性高血压患者中伴有纤维化的比例高于控制型高血压患者。已确定的顽固性高血压与纤维化状况之间的关联可能指向共同的疾病途径,应进一步探索以了解共同的机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European journal of preventive cardiology
European journal of preventive cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
12.50
自引率
12.00%
发文量
601
审稿时长
3-8 weeks
期刊介绍: European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.
期刊最新文献
The Missing Algorithm: Cardiovascular Risk and Menopause Hormone Therapy. Reviving cardiovascular prevention and rehabilitation: what can we learn from China? Cardiovascular Prevention at the Crossroads. Peripheral artery disease: time to recognize the systemic burden and reorganize care. Associations of plant-based diets with all-cause and cause-specific mortality and life expectancy among participants with cardiometabolic disorders from UK, US, and China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1